Clinical Trials by Rheumatology Manchester.

Clinical Trials. 

(Performed within NHS environment)

Prof. Ben Parker is an active researcher and has led several clinical trials in his NHS and research facility roles. These include:

​

UK Chief Investigator Role.

• 2022: National Chief Investigator: A Phase 2 of BMS-986256 in active SLE. BMS.

• 2020: National Chief Investigator: A Phase 2 Study Investigating ABBV-105 and upadacitinib in active SLE. Abbvie.

• 2020: National Chief Investigator: A Phase 2 study of BMS-986165 in Subjects with Lupus Nephritis. BMS.

Principal Investigator.

• 2022: Principal Investigator:  Allegory: Phase 3 study of obinutuzimab in SLE.

• 2020: Principal Investigator: A Phase 2 multicentre trial of CFZ533 in Sjögren’s  Syndrome.

• 2020: Principal Investigator: A Phase 3 multi-centre study of ruxolitinib in COVID-19 associated cytokine storm.

• 2019: Principal Investigator: A Phase 2 study of cerinomod in SLE.

• 2018: Principal Investigator: Healthcare utilisation and QoL in moderate RA.

• 2017: Principal Investigator: BEATLupus - A Phase 2 study of belimumab after SLE.

• 2017: Principal Investigator: TULIP long-term extension study.

• 2016: Principal Investigator: TULIP - a phase 3 study of anifrolumab in SLE.

• 2016: Principal Investigator: An RCT of Rituximab vs. MMF/steroids in Lupus Nephritis.